Divi's Laboratories Limited

BSE:532488 Stock Report

Market Cap: ₹1.5t

Divi's Laboratories Valuation

Is 532488 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 532488 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 532488 (₹5844.75) is trading above our estimate of fair value (₹1299.59)

Significantly Below Fair Value: 532488 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 532488?

Key metric: As 532488 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 532488. This is calculated by dividing 532488's market cap by their current earnings.
What is 532488's PE Ratio?
PE Ratio84.5x
Earnings₹18.36b
Market Cap₹1.55t

Price to Earnings Ratio vs Peers

How does 532488's PE Ratio compare to its peers?

The above table shows the PE ratio for 532488 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average46.9x
SYNGENE Syngene International
70.3x19.3%₹341.1b
INDGN Indegene
37.7x18.4%₹145.1b
AKUMS Akums Drugs and Pharmaceuticals
32.5xn/a₹88.2b
INNOVACAP Innova Captab
47.3x29.7%₹58.2b
532488 Divi's Laboratories
84.5x23.7%₹1.5t

Price-To-Earnings vs Peers: 532488 is expensive based on its Price-To-Earnings Ratio (84.5x) compared to the peer average (46.9x).

Price to Earnings Ratio vs Industry

How does 532488's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
532488 84.5xIndustry Avg. 31.8xNo. of Companies6PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 532488 is expensive based on its Price-To-Earnings Ratio (84.5x) compared to the Asian Life Sciences industry average (31.8x).

Price to Earnings Ratio vs Fair Ratio

What is 532488's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

532488 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio84.5x
Fair PE Ratio54.5x

Price-To-Earnings vs Fair Ratio: 532488 is expensive based on its Price-To-Earnings Ratio (84.5x) compared to the estimated Fair Price-To-Earnings Ratio (54.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 532488 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹5,844.75
₹5,512.44
-5.7%
18.6%₹6,983.00₹3,590.00n/a27
Dec ’25₹6,171.05
₹5,512.44
-10.7%
18.6%₹6,983.00₹3,590.00n/a27
Nov ’25₹5,901.00
₹4,627.31
-21.6%
20.1%₹6,850.00₹3,000.00n/a26
Oct ’25₹5,423.80
₹4,457.08
-17.8%
17.0%₹5,740.00₹3,000.00n/a26
Sep ’25₹5,093.40
₹4,457.08
-12.5%
17.0%₹5,740.00₹3,000.00n/a26
Aug ’25₹4,921.60
₹3,922.42
-20.3%
14.9%₹4,767.00₹2,644.00n/a26
Jul ’25₹4,599.90
₹3,879.88
-15.7%
14.5%₹4,767.00₹2,643.00n/a26
Jun ’25₹4,309.95
₹3,871.33
-10.2%
14.5%₹4,767.00₹2,643.00n/a27
May ’25₹4,000.15
₹3,442.36
-13.9%
13.8%₹4,372.00₹2,541.00n/a25
Apr ’25₹3,567.65
₹3,414.52
-4.3%
13.5%₹4,372.00₹2,541.00n/a23
Mar ’25₹3,478.90
₹3,399.92
-2.3%
13.4%₹4,372.00₹2,541.00n/a24
Feb ’25₹3,654.60
₹3,345.63
-8.5%
14.3%₹4,147.00₹2,344.00n/a24
Jan ’25₹3,912.75
₹3,289.25
-15.9%
14.3%₹4,069.00₹2,344.00n/a24
Dec ’24₹3,792.35
₹3,300.68
-13.0%
14.0%₹4,069.00₹2,344.00₹6,171.0525
Nov ’24₹3,344.80
₹3,361.00
+0.5%
14.2%₹4,300.00₹2,615.00₹5,901.0024
Oct ’24₹3,764.75
₹3,354.38
-10.9%
14.6%₹4,300.00₹2,615.00₹5,423.8024
Sep ’24₹3,588.80
₹3,354.38
-6.5%
14.6%₹4,300.00₹2,615.00₹5,093.4024
Aug ’24₹3,638.80
₹3,097.87
-14.9%
11.5%₹3,610.00₹2,585.00₹4,921.6023
Jul ’24₹3,583.05
₹3,061.41
-14.6%
11.6%₹3,610.00₹2,585.00₹4,599.9022
Jun ’24₹3,524.75
₹3,046.39
-13.6%
12.0%₹3,610.00₹2,450.00₹4,309.9523
May ’24₹3,266.45
₹2,946.30
-9.8%
11.7%₹3,850.00₹2,380.00₹4,000.1523
Apr ’24₹2,825.75
₹2,962.61
+4.8%
13.6%₹3,890.00₹2,380.00₹3,567.6523
Mar ’24₹2,844.60
₹3,024.58
+6.3%
16.3%₹4,450.00₹2,380.00₹3,478.9024
Feb ’24₹3,355.85
₹3,552.96
+5.9%
13.1%₹4,450.00₹2,829.00₹3,654.6024
Jan ’24₹3,412.60
₹3,560.33
+4.3%
12.9%₹4,450.00₹2,829.00₹3,912.7524
Dec ’23₹3,420.25
₹3,560.33
+4.1%
12.9%₹4,450.00₹2,829.00₹3,792.3524

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 12:47
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Divi's Laboratories Limited is covered by 54 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
null nullAntique Stockbroking Ltd.